bioMerieux (OTCMKTS:BMXMF) Shares Climb 8.3% – Still a Buy?

bioMerieux (OTCMKTS:BMXMF) shares rose 8.3% during mid-day trading on Tuesday. The stock traded as high as $95.00 and last traded at $95.00. Approximately 105 shares changed hands during trading, a decline of 71% from the average daily volume of 363 shares. The stock had previously closed at $87.75.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BMXMF. Zacks Research upgraded bioMerieux from a “strong sell” rating to a “hold” rating in a research report on Monday, September 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, Morgan Stanley restated an “underweight” rating on shares of bioMerieux in a research report on Friday, September 11th. Five equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, bioMerieux has a consensus rating of “Reduce”.

bioMerieux Stock Up 4.0%

The company’s fifty day moving average is $84.46 and its two-hundred day moving average is $86.19.

bioMerieux Company Profile

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.